Bioavailability of tolamolol
Bioavailability of tolamolol
复制标题
妥拉洛尔的生物利用度
DOI：
10.1007/bf00561666
复制
发表时间：
1976
影响因子：
2.9
通讯作者：
S. Taylor
中科院分区：
文献类型：
--
作者：
J. Faulkner;D. Stopher;R. Walden;W. Singleton;S. Taylor
在一项双向交叉研究中，通过测量8名健康受试者12小时内托拉洛尔的血浆浓度和最大运动心率的降低，比较了托拉洛尔胶囊和片剂的生物利用度。胶囊中的托莫西汀吸收速度比片剂快;这并未导致两种制剂之间最大运动心率降低的任何显著差异。两种制剂的运动性心动过速降低曲线下面积和托拉洛尔血药浓度曲线下面积无显著差异。最大运动心率的降低与两种制剂给药后2 - 12小时托拉洛尔血浆浓度的对数相关。
Bioavailability of capsule and tablet formulations of tolamolol were compared by measuring plasma concentration of tolamolol and reduction in maximum exercise heart rate over a period of twelve hours in eight healthy subjects in a two-way cross-over study. Tolamol was absorbed more rapidly from capsules than from tablets; this did not result in any significant difference in the reduction in maximum exercise heart rate between the two formulations. There was no significant difference between area under curve of reduction in exercise tachycardia and area under curve of plasma concentration of tolamolol for the two formulations. Reduction in maximum exercise heart rate was related to logarithm of plasma concentration of tolamolol between two and twelve hours after both formulations.